down arrow

DiaMedica Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA25253X2077
USD
8.63
0.65 (8.15%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.448.88

52 Week

3.199.23
Valuation
Technical
Day's Volume

CASH

82.04 k

Shareholding (Mar 2025)

FII

0.53%

Held by 19 FIIs

DII

95.15%

Held by 5 DIIs

Promoter

0.00%

How big is DiaMedica Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, DiaMedica Therapeutics, Inc. has a market capitalization of 153.09 million, with net sales of 0.00 million and a net profit of -27.00 million over the latest four quarters. Shareholder's funds are 40.72 million and total assets are 46.34 million as of Dec 24.

As of Jun 18, DiaMedica Therapeutics, Inc. has a market capitalization of 153.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -27.00 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 40.72 million and Total Assets at 46.34 million.

Read More

What does DiaMedica Therapeutics, Inc. do?

22-Jun-2025

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing recombinant proteins for kidney and neurological diseases, with a market cap of approximately $153.09 million. As of March 2025, the company reported a net profit loss of $8 million.

Overview: <BR>DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of recombinant proteins to treat kidney and neurological diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 153.09 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.07 <BR>Return on Equity: -79.52% <BR>Price to Book: 4.51<BR><BR>Contact Details: <BR>Address: 2 Carlson Pkwy N Ste 260, MINNEAPOLIS MN: 55447-4477 <BR>Tel: 1 763 4965454 <BR>Fax: 1 763 7104456 <BR>Website: https://www.diamedica.com/

Read More

Who are in the management team of DiaMedica Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of DiaMedica Therapeutics, Inc. includes Mr. Richard Pilnik (Independent Chairman), Mr. Rick Pauls (President and CEO), Dr. Harry Alcorn, Mr. James Parsons, Dr. Jerry Xiao, and Dr. Michael Giuffre (Independent Director). They oversee the company's strategic direction and operations.

As of March 2022, the management team of DiaMedica Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Richard Pilnik, who serves as the Independent Chairman of the Board.<BR>- Mr. Rick Pauls, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Harry Alcorn, who is a Director.<BR>- Mr. James Parsons, who is also a Director.<BR>- Dr. Jerry Xiao, who serves as a Director.<BR>- Dr. Michael Giuffre, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is DiaMedica Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, DiaMedica Therapeutics, Inc. has a bullish technical trend, supported by positive MACD indicators and moving averages, while outperforming the S&P 500 with a year-to-date return of 24.49% compared to 12.22%.

As of 9 September 2025, the technical trend for DiaMedica Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by weekly and monthly MACD indicators both showing bullish signals, along with daily moving averages also indicating bullish momentum. The Bollinger Bands reflect a mildly bullish trend on the weekly chart and a bullish trend on the monthly chart. The On-Balance Volume (OBV) is bullish for both weekly and monthly periods, while the KST shows a bullish weekly signal but is mildly bearish on the monthly. The Dow Theory indicates no trend on the weekly chart and a mildly bullish stance on the monthly chart.<BR><BR>In terms of performance, DiaMedica has outperformed the S&P 500 across multiple periods, with a year-to-date return of 24.49% compared to the S&P 500's 12.22%, and a one-year return of 63.68% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 370 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.10

stock-summary
Return on Equity

-108.87%

stock-summary
Price to Book

13.62

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
62.83%
0%
62.83%
6 Months
109.47%
0%
109.47%
1 Year
57.34%
0%
57.34%
2 Years
233.2%
0%
233.2%
3 Years
483.11%
0%
483.11%
4 Years
151.6%
0%
151.6%
5 Years
69.22%
0%
69.22%

DiaMedica Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is DiaMedica Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for DiaMedica Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by weekly and monthly MACD indicators both showing bullish signals, along with daily moving averages also indicating bullish momentum. The Bollinger Bands reflect a mildly bullish trend on the weekly chart and a bullish trend on the monthly chart. The On-Balance Volume (OBV) is bullish for both weekly and monthly periods, while the KST shows a bullish weekly signal but is mildly bearish on the monthly. The Dow Theory indicates no trend on the weekly chart and a mildly bullish stance on the monthly chart. In terms of performance, DiaMedica has outperformed the S&P 500 across multiple periods, with a year-to-date return of 24.49% compared to the S&P 500's 12.22%, and a one-year return of 63.68% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-199.68%
EBIT to Interest (avg)
-18.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.72%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.23
EV to EBIT
-4.86
EV to EBITDA
-4.87
EV to Capital Employed
-62.50
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-79.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (4.32%)

Foreign Institutions

Held by 19 Foreign Institutions (0.53%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -50.98% vs -13.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.00",
          "val2": "-5.60",
          "chgp": "-42.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.70",
          "val2": "-5.10",
          "chgp": "-50.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -25.77% vs -41.61% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.60",
          "val2": "-21.20",
          "chgp": "-25.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.40",
          "val2": "-19.40",
          "chgp": "-25.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.00
-5.60
-42.86%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.70
-5.10
-50.98%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -50.98% vs -13.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.60
-21.20
-25.47%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-24.40
-19.40
-25.77%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -25.77% vs -41.61% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About DiaMedica Therapeutics, Inc. stock-summary
stock-summary
DiaMedica Therapeutics, Inc.
Pharmaceuticals & Biotechnology
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins. The Company uses its technologies for the development and commercialization of recombinant proteins to treat kidney and neurological diseases. The Company’s focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). The Company’s lead product DM199, is a drug candidate, a commercial potential as a therapy for CKD and AIS. DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands that plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in inflammation and oxidative stress.
Company Coordinates stock-summary
Company Details
2 Carlson Pkwy N Ste 260 , MINNEAPOLIS MN : 55447-4477
stock-summary
Tel: 1 763 4965454
stock-summary
https://www.diamedica.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."